Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019
June 05 2019 - 4:00PM
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
today announced the planned retirement of its chief scientific
officer, Scott Biller, Ph.D. Dr. Biller will retire from his CSO
position at the end of 2019 and continue to serve as a strategic
advisor through the end of 2020. The company has initiated a search
to identify his successor.
“Scott has been instrumental to Agios’ success
over the past nine years, guiding the incredible productivity of
our research organization and cultivating a great group of senior
leaders responsible for Agios’ groundbreaking scientific
discoveries. Under his leadership, the team has built a robust
preclinical pipeline and advanced seven molecules into the clinic
that resulted in two marketed therapies and multiple late-stage
clinical programs,” said Jackie Fouse, Ph.D., chief executive
officer at Agios. “Scott’s retirement is well earned and marks the
pinnacle of his accomplished career. As we search for our next
great scientific leader, we are grateful that we will continue to
benefit from Scott’s insight and have his assistance to ensure a
smooth transition to his successor.”
“It has been a privilege and honor to be a part
of the Agios team for nearly a decade and to work toward our shared
vision of making a meaningful impact on the lives of patients,”
said Dr. Biller. “The quality of our science and success of our
programs has always been a team effort, and I have full confidence
in our research team to continue to reach for the ‘other side of
possible’ in all the work that we do.”
About AgiosAgios is focused on
discovering and developing novel investigational medicines to treat
cancer and rare genetic diseases through scientific leadership in
the field of cellular metabolism and adjacent areas of biology. In
addition to an active research and discovery pipeline across both
therapeutic areas, Agios has two approved oncology precision
medicines and multiple first-in-class investigational therapies in
clinical and/or preclinical development. All Agios programs focus
on genetically identified patient populations, leveraging our
knowledge of metabolism, biology and genomics. For more
information, please visit the company's website at
www.agios.com.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include those regarding: the expected outcomes of Agios’
chief scientific officer transition plan; Agios’ discovery,
development and commercialization capabilities; and Agios’
competitive position, strategic plans and focus. The words
“anticipate,” “believe,” “could,” “estimate,” “expect,” “hope,”
“intend,” “may,” “milestone,” “path”, “plan,” “possible,”
“potential,” “predict,” “prepare”, “project,” “strategy,”
“will,” “would,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from Agios'
current expectations and beliefs. For example, there can be no
guarantee that any product candidate Agios or its collaborators is
developing will successfully commence or complete necessary
preclinical and clinical development phases, or that development of
any of Agios' product candidates will successfully continue.
Moreover, there can be no guarantee that the medicines being
commercialized by Agios and its collaborators will receive
commercial acceptance. There can be no guarantee that any positive
developments in Agios' business will result in stock price
appreciation. Management's expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
important factors, including: Agios' results of clinical trials and
preclinical studies, including subsequent analysis of existing data
and new data received from ongoing and future studies; the content
and timing of decisions made by the U.S. FDA and other regulatory
authorities, investigational review boards at clinical trial sites
and publication review bodies; Agios' ability to obtain and
maintain requisite regulatory approvals and to enroll patients in
its planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios'
ability to maintain key collaborations; and general economic and
market conditions. These and other risks are described in greater
detail under the caption "Risk Factors" included in Agios’ public
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor & Media
ContactHolly Manning, 617-844-6630Associate Director,
Investor RelationsHolly.Manning@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Sep 2023 to Sep 2024